Spring Builders: thomas schmitt

Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics

thomas schmitt — Mon, 20 Jul 2026 09:13:31 +0000

Lysosomes are essential organelles in eukaryotic cells that are responsible for a variety of functions, including endocytic degradation, extracellular secretion, and signal transduction. Dozens of proteins are localized to the lysosomal membrane, where they regulate the transport of ions and substances across the membrane. These proteins are crucial to lysosomal function. Mutations or abnormal expression of these proteins can trigger various diseases, making them potential targets for the development of drugs aimed at treating lysosomal disorders. However, further breakthroughs in this field of research require a deeper understanding of the underlying mechanisms by which abnormalities in these membrane proteins induce associated diseases.

As complex drug modalities such as antibody-drug conjugates (ADCs) and oligonucleotide therapies (including mRNA, siRNA and circular RNA) dominate the preclinical development pipeline, it is of paramount importance to understand their intracellular fate. A major bottleneck in these workflows is the in vitro simulation of the lysosomal environment. Due to physical density overlap, standard differential centrifugation often contaminates lysosomal fractions with mitochondria, which distorts metabolic and pharmacokinetic data.

To support this research, Creative Diagnostics has overcome this technical challenge with its TriLS™ Tritosome separation technology. This technology uses the tissue-specific endocytosis of the non-ionic surfactant Tyloxapol (Triton WR-1339) to selectively alter the buoyant density of target lysosomes. This enables pure, high-resolution separation via density gradient centrifugation, effectively removing over 90% of mitochondrial cross-contamination while preserving active lysosomal hydrolases.

The Tritosomes supplied by Creative Diagnostics play a key role in advancing research into ADCs by providing a pure model for the study of lysosomal uptake, processing, and payload release. Tritosomes enable researchers to gain in-depth knowledge of linker chemistry, cleavage efficiency, payload release patterns and species-specific differences in drug release. This helps to optimize the stability and efficacy of ADCs, achieving better therapeutic outcomes.

A key challenge in the research of small-molecule nucleic acid drugs is that most oligonucleotides are captured by endosomes and lysosomes. If they cannot escape these organelles and enter the cytoplasm, they are rapidly degraded and lose their therapeutic activity. Against this backdrop, Creative Diagnostics' Tritosomes provide a controlled in vitro system for studying the degradation kinetics of unmodified and chemically modified nucleic acid drugs.

Researchers can use these Tritosomes to evaluate the protective effect of chemical modifications against lysosomal degradation and assess the efficacy of delivery systems designed to facilitate endosomal escape. Consequently, Creative Diagnostics' Tritosomes are crucial for optimizing drug stability and refining delivery strategies prior to progressing to more complex animal models.

To explore technical specifications, review workflow diagrams, or request a quote, please visit the official product page at https://qbd.creative-diagnostics.com/trils-tritosome.html.

About Creative Diagnostics

Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.

Respiratory Syncytial Virus Animal Model Services for Antiviral and Vaccine Discovery

thomas schmitt — Mon, 20 Jul 2026 09:10:14 +0000

hRSV is a leading cause of respiratory illness and hospitalization in infants worldwide and also contributes significantly to the marked rise in morbidity among adults and premature mortality in the elderly. The number of vaccine candidates being developed for high-risk populations susceptible to hRSV infection is steadily increasing. Animal models of hRSV play a crucial role in the preclinical testing of these candidates. While many candidates have demonstrated efficacy in preclinical studies, few have progressed to clinical trials, achieving only limited success. This is partly due to the lack of animal models that can fully replicate the pathogenesis of human RSV infection.

With the exception of chimpanzees, other non-human primates (NHPs) are only partially susceptible to hRSV replication. Even following experimental infection with high viral doses, they rarely exhibit clinical symptoms or only mild ones, and typically display only minor pulmonary pathological changes. Other animal models, such as cotton rats, mice, ferrets, guinea pigs, hamsters, chinchillas, and newborn lambs, also exhibit only partial susceptibility to hRSV. Nevertheless, mice and cotton rats remain significant in developing monoclonal antibody prophylactic therapies for high-risk infants and in providing insights into the immunological mechanisms and pathogenesis of respiratory syncytial virus.

RSV animal models are invaluable tools for studying the complex dynamics of RSV infection, evaluating potential therapeutic agents, and developing effective vaccines. Creative Diagnostics provides clients with reliable respiratory syncytial virus animal models to support the development of therapeutics and vaccines, thanks to its advanced animal modelling techniques and unrivalled expertise in the field of infectious diseases.

The company's team of experts will select the most suitable models for each client, such as the cotton rat or mouse models, based on the type of infection under investigation and the proposed research hypotheses. The company offers a comprehensive range of services to support RSV animal model research, including study design and execution, pathological analysis, immune response profiling, in vivo pharmacokinetic studies, and pharmacodynamic, efficacy and toxicity assessments.

Creative Diagnostics' RSV animal models have a wide range of applications in advancing RSV research, vaccine development, and drug discovery. They enable researchers to evaluate the immunogenicity and efficacy of potential RSV vaccine candidates in preclinical studies, investigate pathogenic mechanisms and identify new therapeutic targets, and assess the safety and efficacy of antiviral compounds and immunomodulators.

For more information about Creative Diagnostics' Respiratory Syncytial Virus Animal Model services and broader virology portfolio, please visit https://antiviral.creative-diagnostics.com/respiratory-syncytial-virus-animal-model.html.

About Creative Diagnostics

Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Hantavirus Research Reagents and Products to Accelerate Global Diagnostic and Vaccine Research

thomas schmitt — Mon, 20 Jul 2026 05:57:44 +0000

Hantaviruses are emerging zoonotic pathogens that belong to the Bunyaviridae family. The US Centers for Disease Control and Prevention (CDC) classifies them as Category A pathogens. They pose a serious threat to human health as their infection can lead to haemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS), both of which are highly fatal. These pathogens are transmitted to humans via aerosols containing the excreta of infected rodent hosts.

Hantaviruses possess a tripartite negative-strand RNA genome. The three genomic RNA segments (S, M and L) encode the nucleocapsid protein (N), a precursor glycoprotein (which forms two envelope glycoproteins, Gn and Gc upon processing), and the viral RNA-dependent RNA polymerase (RdRp). The N protein is the virus's primary structural component and its main function is to protect and encapsulate the three genomic RNA strands to form three viral ribonucleocapsids. Recent studies suggest that the N protein acts in concert with RdRp to play a crucial role in the transcription and replication of the viral genome. Furthermore, the N protein preferentially promotes the translation of viral mRNA within the cell.

There are currently no antiviral therapies or vaccines available to treat hantavirus-associated diseases. A deeper understanding of the molecular mechanisms underlying the hantavirus life cycle could help to identify targets for antiviral therapy and design potential antiviral drugs to treat HFRS and HCPS. In view of the alarming case-fatality rate of hantavirus diseases, the development of an effective hantavirus vaccine is imperative.

As the early clinical manifestations of hantavirus infection are often similar to common seasonal respiratory or influenza-like illnesses, there is an urgent need for highly sensitive, reliable and standardized laboratory diagnostic tools to enable early differential diagnosis and accurate target validation. To address these research challenges, Creative Diagnostics offers a range of hantavirus research reagents and products covering multiple strains, including Hantavirus, Puumala virus (PUUV), Seoul virus (SEOV) and Sin Nombre virus (SNV).

Creative Diagnostics' new product line includes: 1) Recombinant hantavirus antigens for assay development; 2) high-affinity monoclonal and polyclonal antibodies, which have been validated for capture and detection uses across multiple platforms, including Western blot, flow cytometry, immunohistochemistry and surface plasmon resonance; 3) supporting reagents for ELISA and rapid immunoassay research.

For detailed product specifications, volume pricing, or to browse the complete list of available viral solutions, please visit the official product portal at https://www.creative-diagnostics.com/hantavirus.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.

Flow Cytometry Antibodies to Advance Non-Human Primate Research

thomas schmitt — Thu, 28 May 2026 07:22:35 +0000

Although non-human primates account for only a small proportion of the animals used in biomedical research, they remain important research models due to their high degree of similarity to humans in terms of genetic makeup, anatomy, physiology and behaviour. Key medical advances have been driven by research conducted using non-human primates, primarily monkeys, saving or improving the lives of millions of people.

Prior to clinical trials, NHP models play a crucial role in evaluating therapeutic antibodies, biologics, and immunomodulatory drugs. Flow cytometry has become an essential analytical tool for studying immune responses in these models. Enabling high-dimensional analysis of immune cell populations and their activation states, it allows researchers to assess changes in immune cell subsets, functional markers, and cytokine expression in response to drug candidates, vaccines, or disease progression.

However, researchers often face a significant challenge in the form of the limited availability of antibodies that are specifically validated to target monkey immune markers. This means that many laboratories are forced to rely on anti-human antibodies that exhibit cross-reactivity, which can lead to inconsistent results, weak signals or poor reproducibility.

To address this issue, Creative Diagnostics has developed a portfolio of high-quality antibodies that target monkey immune cell surface markers specifically. These antibodies enable precise immune monitoring and support the reliable phenotyping of non-human primate immune systems and translational research.

Creative Diagnostics' rabbit anti-monkey flow cytometry antibody panel has been developed to detect surface markers on monkey immune cells. Designed to support preclinical pharmacology studies, immune profiling and mechanistic research in non-human primate models, these antibodies help pharmaceutical and biotechnology companies to accelerate the development of innovative therapies.

The panel enables precise characterization of immune cell subsets and signaling pathways involved in drug responses, disease progression, and immune regulation in NHP research. The broad coverage of markers allows researchers to construct multiparametric flow cytometry panels and facilitates in-depth immunophenotyping analyses in non-human primates.

Furthermore, these antibodies have been optimized to exhibit high specificity for non-human primate antigens, enabling the accurate detection of primate immune markers with minimal background signal. All the antibodies in this panel are produced using recombinant antibody technology and demonstrate an excellent signal-to-noise ratio.

These rabbit anti-monkey flow cytometry antibodies are ideal for various applications in NHP research, including preclinical drug development, immunophenotyping, mechanism of action studies and safety and immunotoxicity assessments. For more information about the Rabbit Anti-Monkey Flow Cytometry Antibody Panel or to view the full product catalog, please visit https://www.creative-diagnostics.com/flow-cytometry-antibodies-for-non-human-primate-research.htm.

About Creative Diagnostics

Preclinical Support with Advanced Coronavirus Animal Model Services for Antiviral Research

thomas schmitt — Mon, 25 May 2026 05:46:54 +0000

The Coronavirus Disease 2019 (COVID-19) pandemic has led to the rapid development of animal models to help us understand the disease's pathogenesis, test treatments and support vaccine development. Models previously established for studying severe acute respiratory syndrome coronavirus (SARS-CoV) have been rapidly adapted for SARS-CoV-2 research. However, despite both viruses utilizing ACE2 as their receptor, it is clear that their host ranges do not fully overlap. SARS-CoV and SARS-CoV-2 have different residues that interact with ACE2 within their receptor-binding domains. Furthermore, there are species-specific differences in the proteases required for viral activation and internalization, which are likely responsible for the differences in host range between the two viruses. Natural host models include rhesus macaques, long-tailed macaques, African green monkeys, hamsters and ferrets.

Animal models are an indispensable component of research into COVID-19. While in vitro, ex vivo and organoid models have revealed key virological characteristics of SARS-CoV-2, animal models that can reproduce the clinical and pathological features of human COVID-19 are essential for investigating the virus's pathogenic mechanisms, transmission routes, potential therapeutics and vaccines. Insights into pathogenic mechanisms and virus-host interactions derived from in vitro studies require validation through animal models to confirm their physiological relevance. Novel antiviral drugs must be evaluated in animal models because characteristics such as bioavailability, serum concentrations, half-lives and tissue distribution can only be assessed in vivo. Similarly, transmission and vaccine research can only be evaluated using physiologically relevant animal models.

Creative Diagnostics is dedicated to delivering innovative solutions for studying coronaviruses, including developing and applying animal models. Drawing on its extensive experience in this field, Creative Diagnostics offers a comprehensive range of services to support research into animal models of coronaviruses, specifically tailored to the needs of researchers and pharmaceutical companies. These services include study design and execution, pathological analysis and immune response profiling, and the efficacy testing of vaccines and antiviral compounds, as well as data analysis and interpretation.

While a variety of animal models are currently available, none can fully replicate all the pathological features of human Coronavirus infection. Creative Diagnostics' research team has an in-depth understanding of the strengths and weaknesses of various animal models, and can optimize them to help researchers achieve their scientific objectives. The Coronavirus animal models include SARS-CoV Virus Intranasal Infection Rhesus Monkey Model, SARS-CoV Virus Intranasal Infection Mouse Model, and SARS-CoV-2 Syrian Hamster Model.

For more information regarding the Coronavirus Animal Model services or to request a project consultation, please visit https://antiviral.creative-diagnostics.com/coronavirus-animal-model.html.

SpeX™ Gerbillinae Liver Microsomes to Advance In Vitro Drug Metabolism Research

thomas schmitt — Fri, 22 May 2026 02:46:00 +0000

The Gerbillinae subfamily is the second largest within the Muridae family, after the Murinae subfamily, comprising approximately 16 genera and over 100 species. The phylogenetic relationships among the major clades within the Gerbillinae remain unclear. One of the main issues concerns the phylogenetic position of the monotypic genus Ammodillus, which is endemic to the Horn of Africa. Based on morphological data, this genus may represent one of the earliest branches of the Gerbillinae main clade. However, due to a lack of genetic data, its precise taxonomic placement has not yet been determined.

The Gerbillinae subfamily includes gerbils and sand rats, both of which are adapted to arid and semi-arid environments. Species within this subfamily possess highly efficient water conservation capabilities, unique metabolic regulation mechanisms, and physiological adaptations. These characteristics distinguish them from commonly used laboratory rodents, such as mice and rats.

In drug research, species of the Gerbillinae subfamily play a vital role as valuable preclinical research models. Their unique cerebral vascular anatomy makes them particularly well-suited to studies of cerebral ischaemia, stroke, and neuroprotective therapies. Furthermore, Gerbillinae models are widely used in neuroscience, auditory research, epilepsy research and infectious disease research, as the progression of disease and pharmacological responses they exhibit often more closely mirror those observed in humans.

From a pharmacological perspective, species in the Gerbillinae subfamily have unique characteristics that influence drug efficacy, pharmacodynamics, and metabolism under various physiological conditions. Differences in their metabolic pathways and tissue sensitivity provide important insights into species-specific drug responses, helping to bridge the gap between traditional rodent models and human translational research. Consequently, Gerbillinae models are playing an increasingly important role in innovative drug discovery and translational research.

Drawing on years of expertise in the field of in vitro biological reagents, Creative Diagnostics has developed the SpeX™ Gerbillinae liver microsome model to support researchers' drug metabolism studies. The launch of the model enables scientists to utilize these unique metabolic characteristics within a controlled, high-throughput in vitro environment.

These new liver microsomes have been carefully developed to provide a reliable and translationally relevant in vitro model that supports research into cholesterol metabolism, diabetes, neuroprotection, epilepsy, and the development of anti-parasitic drugs. For more information about SpeX™ Gerbillinae Liver Microsomes or to explore the full range of ADME products and services, please visit https://qbd.creative-diagnostics.com/spex-gerbillinae-liver-microsomes.html.

About Creative Diagnostics